

CLINUVEL Group

ASX:

Level 1 ADR (Nasdaq Int'l Designation):

XETRA-DAX:

CUV
CLVLY
UR9

clinuvel.com

news.clinuvel.com



CLINUVEL Investor Webinar

Shareholder Questions Answered

25 October 2021

Moderated by

Mr Malcolm Bull

Head of Investor Relations

with

Dr Philippe Wolgen

Managing Director

Legal Notice

This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL's management. Statements may involve a number of known and unknown risks that could cause our future results, performance or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize pharmaceutical products, the COVID-19 pandemic affecting the supply chain for a protracted period of time, including our ability to develop, manufacture, market and sell biopharmaceutical products; competition for our products, especially SCENESSE® (afamelanotide 16mg); our ability to achieve expected safety and efficacy results through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, China and Japan of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in

the outsourced manufacturing of SCENESSE® which may lead to it being unable to supply its commercial markets and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology and consumer based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; any failure to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2021 Annual Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on the forecasts and estimates is available on request. Past performance is not an indicator of future performance.

Key Events FY2021

1. Strong Financial Performance


| | |
|--------------------------|---------------------------|
| Revenues: | ↑ 43% to A\$48.5 million |
| Net Profit (before tax): | ↑ 123% to A\$25.7 million |
| EPS: | ↑ 64% to A\$0.50 |

2. Increased Access to SCENESSE®: Europe & US

3. Growth: Four Divisions

4. R&D Expansion

5. Start of Stroke Program; XP (NPP)



CLINUVEL's Strategic Path

Multi-pronged Strategy


Expansion

1. Afamelanotide in Multiple Indications
2. Portfolio of Melanocortins
3. Targeted Technology Translation



Vitiligo

1. Viable Study Design (CUV104)
2. Meaningful Endpoints
3. Impact of Disease
4. Minimal Important Difference



CUV102 participant, image courtesy of the investigator



Your Questions on **New Indications**

What can we expect?

Key Outputs 2022

1. Expansion & Distribution SCENESSE®
2. Progress DNA Repair Program
 - XP Studies
 - Unattended Photodamage - OTC
3. Complete First Stroke Study (CUV801)
4. Vitiligo Program (CUV104)
5. New Indication

Strategic Update III before AGM

CLINUVEL Group

ASX:

Level 1 ADR (Nasdaq Int'l Designation):

XETRA-DAX:

CUV

CLVLY

UR9

clinuvel.com

news.clinuvel.com



Thank You

For Your Attention

Moderated by

Mr Malcolm Bull

Head of Investor Relations

with

Dr Philippe Wolgen

Managing Director